CAPhO Conference 2021

Program at a Glance

Jump to date

2021-06-03 June 3, 2021
2021-06-04 June 4, 2021
2021-06-05 June 5, 2021
2021-06-06 June 6, 2021

Note: Program is subject to change. All times indicated are Eastern Daylight Time (EDT).

To view session descriptions click on "More Info" and then click on the presenter's name to view their biography.

Thursday
June 3, 2021
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
Pfizer - Applying Real World Evidence for CDK4/6 Inhibitors in advanced Breast Cancer (aBC) and Discussing new RWE in Biosimilars
Presenters
Kimberly Kuik
Leigh Revers
Photo of Kimberly Kuik
Photo of Kimberly Kuik
Kimberly Kuik
BScPharm
Pharmacy Professional Practice Leader, Pharmacy, BC Cancer — Victoria, British Columbia
Kimberly Kuik
BC Cancer, Victoria, British Columbia
Leigh Revers
M.Sc., Ph.D.
Director MBiotech, University of Toronto — Toronto, Ontario
Leigh Revers
University of Toronto, Toronto, Ontario

The availability of real world evidence (RWE) is pertinent in assessing patient outcomes, but how does one start to utilize this data? This program will discuss how to assess RWE and enrich clinical practice through two important oncology discussions. The first segment, presented by Kimberley Kuik, will analyze and discuss the application of RWE in CDK4/6 inhibitors in advanced breast cancer (aBC). The second segment, presented by Dr. Leigh Revers, will assess recent RWE in oncology biosimilars.  Join us as we explore and discuss real-world evidence (RWE) and how it can inform Canadian oncology practice. 

Friday
June 4, 2021
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
Janssen - Optimizing Care for Patients with CLL
Presenters
Tina Crosbie
Photo of Tina Crosbie
Photo of Tina Crosbie
Tina Crosbie
Clinical Pharmacist - Hematology, Pharmacy, The Ottawa Hospital — Ottawa, Ontario
Tina is the clinical pharmacist in the hematology chemotherapy unit at The Ottawa Hospital. Here she oversees patients with lymphomas, multiple myeloma and chronic lymphocytic leukemia who are receiving care on an outpatient basis. Tina joined the hematology team at The Ottawa Hospital in 1999. Tina has written educational materials and has given presentations on topics in hematology and patient care. She enjoys being a peer reviewer for CCCEP, is Past President of CAPhO and serves on the Oncology Fundamental Day (OFD) education committee. Tina was honoured to chair the 2018 CAPhO conference in Ottawa. Tina received her Bachelor of Science in Pharmacy at Memorial University of Newfoundland and completed an accredited residency in hospital pharmacy in Ottawa.
Tina Crosbie
The Ottawa Hospital, Ottawa, Ontario

Learning Objectives:

  1. Review long-term data supporting the use of current therapies for CLL;
  2. Recognize potential adverse events that may occur with select therapies for CLL and how best to manage them; and
  3. Identify points to consider when discussing treatment expectations with a patient.
Welcome and Plenary session
Managing the Challenge of New Oral Cancer Treatment Medications
Presenters
Mario de Lemos
Khushminder Rai
Photo of Mario de Lemos
Photo of Mario de Lemos
Mario de Lemos
Pharmacy Professional Practice Leader, Provincial Pharmacy, Systemic Therapy Program, BC Cancer — Vancouver, British Columbia
Mario de Lemos
BC Cancer, Vancouver, British Columbia
Photo of Khushminder Rai
Photo of Khushminder Rai
Khushminder Rai
Pharmacy Educator / Clinical Pharmacist, BC Cancer Pharmacy Community Oncology Network / BC Cancer Surrey — Surrey, British Columbia

Khushminder is a Pharmacy Educator for BC Cancer Pharmacy Community Oncology Network (CON). She has a BSc. Pharmacy degree from University of British Columbia and a Community Pharmacy Residency. She liases with the CON sites in the community to ensure safe and effective cancer drug therapy is delivered at all sites. She is a part of the team that develops oncology education material for BC Cancer and CON Pharmacy staff. She also works as a Clinical Pharmacist at BC Cancer Surrey.

Khushminder Rai
BC Cancer Pharmacy Community Oncology Network / BC Cancer Surrey, Surrey, British Columbia

The rapid advance of oral oncology therapeutics means that general pharmacy practitioners need to be familiar with the mechanisms of actions involving many new genetic and molecular targets. This presentation will describe the mechanisms of actions of selected classes of new oral agents, and provide resources and tools for general pharmacy practitioners to learn more about managing oral oncology drugs.

Learning Objectives:

  1. Understand the importance of knowing more about oral oncology drugs in clinical practice;
  2. Describe the mechanisms of actions of selected groups of recently introduced oral oncology drugs (approved within last 5 years); and
  3. Describe some tools and resources that can be used to learn more about these drugs.
Networking Session
Break
Break amongst the Exhibits and Posters
Concurrent session
Chemotherapy Checking for Technicians: Alberta's Journey
Presenters
J. Robin Burns
Photo of J. Robin Burns
Photo of J. Robin Burns
J. Robin Burns
Pharmacy Operations Manager , CancerControl Alberta Pharmacy, Alberta Health Services — Edmonton, Alberta

Robin graduated from Red Deer College in 1993 and has spent most of her career in retail with Shoppers Drug Mart. Eventually she left retail and spent 5 years at Alberta Blue Cross publishing and managing the Alberta Health and Wellness Drug Benefit List on behalf of the Alberta government.

 

More recently, she has been a staff technician at the Cross Cancer Institute for 3 years where she was one of the cytotoxic IV admixture trainers for the Community Cancer Network.  Today, she is the Pharmacy Operations Manager for the Cancer Network for CancerControl Alberta Pharmacy. Robin also served as a Pharmacy Technician Observers on the council for the Alberta College of Pharmacists from 2008-2014 as Alberta moved towards Pharmacy Technician Regulation and is now a regulated technician herself.

J. Robin Burns
Alberta Health Services, Edmonton, Alberta

In the province of Alberta, pharmacy technicians traditionally have not performed tech check tech duties for oral and parenteral chemotherapy preparations. As technician regulation came into force on January 1, 2016 CancerControl Alberta (CCA) Pharmacy was faced with a technician workforce that had a new expanded scope of practice and professional responsibilities. As a result, in the spring of 2015 CCA Pharmacy began to look at workforce optimization and developed a certification program to have technicians fill the role of chemotherapy checkers in order to allow technicians to practice to their full scope while at the same time supporting pharmacists in expanding clinical roles within CCA Pharmacy. Although technicians are the main focus of the chemotherapy checking certification program, it is also applicable to new and existing pharmacists within CCA Pharmacy.

Learning Objectives:

  1. Be able to identify CCA Pharmacy’s policies and procedures for Authorized Chemotherapy Checking certification;
  2. Be able to identify 3 tools developed or the Authorized Chemotherapy Checker certification program;
  3. Be able to identify 5 critical steps in CCA Pharmacy’s embedded worksheets and checking process; and
  4. Gain the tools to be able to develop a chemotherapy checking certification program/process for pharmacy technicians (and pharmacists).
Concurrent session
So, You Have A Research Idea. What Now?
Presenters
Thomas McFarlane
Photo of Thomas McFarlane
Photo of Thomas McFarlane
Thomas McFarlane
Clinical Lecturer/Researcher, Pharmacy, University of Waterloo — Kitchener, Ontario
Tom is currently a Clinical Lecturer and a researcher at the University of Waterloo School of Pharmacy in Kitchener, Ontario, where he created, coordinates, and teaches the oncology portion of the curriculum in the Doctor of Pharmacy program and conducts practice based research.
Thomas McFarlane
University of Waterloo, Kitchener, Ontario

Research is within the purview of many oncology pharmacists, but as a profession we often don’t see ourselves as researchers. Even if we have a research idea, sometimes it’s difficult to know how to get started, especially for those not working in a teaching or academic centre. Although there are barriers to conducting research in the oncology pharmacy world, it is still something that can be done with the right supports and strategies. This presentation will give a high-level overview of the steps involved in taking a research question forward to a full project.

Learning Objectives:

  1. Understand what makes a good research question;
  2. Recognize strategies for answering a given research question;
  3. Understand the elements of a successful research proposal;
  4. Explain the ethics of research with human participants and how to navigate ethics applications; and
  5. Summarize the components of a successful grant application.
Concurrent session
Common Infections in the Malignant Hematology Patient Population
Presenters
Samantha Polito
Photo of Samantha Polito
Photo of Samantha Polito
Samantha Polito
Pharmacist, Pharmacy, Princess Margaret Cancer Centre - University Health Network — Toronto, Ontario
Samantha Polito
Princess Margaret Cancer Centre - University Health Network, Toronto, Ontario

Patients with a hematological malignancy often present with infectious complications. During their disease trajectory, it is estimated that 80% of these patients will experience an episode of febrile neutropenia; 70-80% of these episodes will not have an identifiable source. Others are found to be caused by a multitude of different infections. Management of these patients, including transitioning these patients to the ambulatory setting while still on treatment, remains a major challenge for oncology pharmacists and the multidisciplinary health care team. In this presentation, I will review febrile neutropenia as an infectious syndrome, and discuss central line infections, lower respiratory tract infections (focusing on fungal pneumonia), and CMV mucositis as infections commonly seen in this patient population.

Learning Objectives:

  1. Identify reasons why malignant hematology patients are at risk for infectious complications;
  2. Review Febrile Neutropenia as an infectious syndrome commonly seen in malignant hematology patients;
  3. Describe the management of central line infections, lower respiratory tract infections, and CMV mucositis; and
  4. Discuss difficulties and potential risks of infection management in the malignant hematology patient transitioning to the ambulatory setting.
Satellite symposium
La Roche-posay Laboratoire Dermatologique - The Multi-Disciplinary Approach to Preventing Cutaneous Toxicity in Patients Receiving Oncology Treatments: Role of the Pharmacist
Presenters
Dr. Tarek Hijal
Dr. Tarek Hijal
MDCM, MSc, FRCPC
Director, Division of Radiation Oncology, McGill University Health Centre and RI-MUHC — Montreal, Quebec

Associate Professor, Department of Oncology, McGill University, Montreal, QC

Dr. Tarek Hijal
McGill University Health Centre and RI-MUHC, Montreal, Quebec

As the prevalence of cancer increases, now affecting one in two Canadians, so does the frequency of adverse events relate to anti-cancer therapies. Oncology protocols have evolved, which has led to an improvement in patient prognosis and overall survival. However, those treatments are associated with adverse cutaneous side effects, which can impair a patient’s quality of life and result in dose reductions or discontinuations that could be detrimental for the outcome of the patient. Studies confirm that appropriate management is therefore necessary. 

Proper adjunctive management and palliative care can lead to an improvement in patient quality of life for patients experiencing skin toxicities from oncology treatments. 
 

Saturday
June 5, 2021
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
Takeda - The Role of Real World Evidence (RWE) in Cancer Care
Presenters
Winson Y. Cheung
Winson Y. Cheung
MD, MPH, FRCPC
Professor , Departments of Medicine and Oncology , University of Calgary — Calgary, Alberta

Director | Real-World Evidence | Cancer Care Alberta
Medical Oncologist | Section of Medical Oncology | Tom Baker Cancer Centre
 

Winson Y. Cheung
University of Calgary, Calgary, Alberta

The future of how real world evidence (RWE) can be used to inform clinical practice, drive more rigorous HC and health technology assessment, and provide patient’s perspective on the value of oncology medicines.

Learning Objectives:

  1. To understand the current landscape and future framework for the use of RWE in Health Canada (HC) and Health Technology Assessment (HTA) for oncology medicines;
  2. To discuss how the future frame work incorporating RWE will impact patient treatment and management; and
  3. To discuss specifically how real-world derived patient/caregiver reported quality of life (QoL) and other outcomes should be incorporated into HC and HTA decisions and patient management.
Plenary session
The Expanding Role of Immunotherapy
Presenters
Rose-Marie Reddy
Photo of Rose-Marie Reddy
Photo of Rose-Marie Reddy
Rose-Marie Reddy
Pharmacist, BC Cancer — Abbotsford, British Columbia
Rose-Marie has worked as a clinical pharmacist with BC Cancer at Abbotsford Regional Hospital for the past 13 years, developing a passion for oncology. Rose-Marie holds a B.Sc in Pharmacy from Dalhousie University (2009) and a PharmD for Pharmacists Degree from University of Toronto (2019).
Rose-Marie Reddy
BC Cancer, Abbotsford, British Columbia

The role for immunotherapy in cancer treatment continues to expand. We will review the changes, challenges, and opportunities that immunotherapy presents in our oncology practice. Recent evidence for the use of checkpoint inhibitors includes:

  • atezolizumab in combination with bevacizumab in hepatocellular carcinoma
  • ipilimumab plus nivolumab in combination with chemotherapy in non-small cell lung carcinoma
  • nivolumab as adjuvant therapy in resected esophageal or gastroesophageal junction cancer.

With an increase in the use of checkpoint inhibitors, we will discuss on-going challenges in managing immune-related adverse events. We will also look towards future opportunities for immunotherapy being studied in oncology.

Learning Objectives:

  1. Describe the expanding role of immunotherapy in cancer treatment;
  2. Recognize challenges in managing immune-related adverse events; and
  3. Understand future opportunities for use of immunotherapy being studied in Oncology:
    • As tumour agnostic therapy
    • In combination with radiation therapy (abscopal effect).
Networking Session
Annual General Meeting (AGM)

To view the AGM Agenda, last year's AGM minutes and Committee reports go to the Community Centre and click on 'Upcoming Events' then 'CAPhO 2021 AGM'. 

Break
Break amongst the Exhibits and Posters
Concurrent session
Advanced Pharmacy Technician Scope of Practice: What We Can Do for You
Presenters
Cloë Cullen
Photo of Cloë Cullen
Photo of Cloë Cullen
Cloë Cullen
Pharmacy Technician, Fraser Health — Abbotsford, British Columbia

Cloë Cullen is a Regional On-Call Pharmacy Technician from Abbotsford, BC. She has been with Fraser Health for 8 years and has over 10 years of pharmacy experience across hospital, community, and long-term care settings as well as instructing in accredited pharmacy programs throughout the Lower Mainland. Her work with Fraser Health has expanded from the pharmacy department into staff engagement endeavours and conducting various studies in partnership with laboratory and library services. Cloë recently completed the BCIT Health Leadership program where her Capstone project focused on implementing standardized training and continuing education platforms to reduce medication turnaround time and dispensing errors.

Cloë Cullen
Fraser Health, Abbotsford, British Columbia

To fully understand how a pharmacy technician can benefit and aid in interdisciplinary settings, we must first dive into the history and making of the registered pharmacy technician’s scope of practice. Who we are, what we can do, and where we are doing it, is the focus of this presentation. Together will peer into the world of a clinical technician and see what how their tools can help unburden your everyday clinical practice.

Learning Objectives:

  1. To summarize the evolving evidence for the regulated pharmacy technician advancement into clinical roles;
  2. Identify efficiency contributions technicians make to a pharmacy and multidisciplinary team; and
  3. To brainstorm future opportunities for utilizing regulated pharmacy technicians.
Concurrent session
Plant-Based Cannabis Use in Oncology: Evidence Based Practice Versus Patient Focused Care
Presenters
Carlo DeAngelis
Carlo DeAngelis
Clinician Scientist, Pharmacy, Sunnybrook Odette Cancer Centre — Ancaster, Ontario
Carlo DeAngelis
Sunnybrook Odette Cancer Centre, Ancaster, Ontario

Canadians have a long standing interest in using plant derived cannabinoids (cannabis) for medical purposes. Despite the lack of evidence, cancer patients have a desire to use cannabis for cancer and treatment related symptoms as well as an anticancer strategy.

This presentation will review the current legislative framework for cannabis use, explore reasons for use by cancer patients and summarize the current evidence supporting cannabis use in oncology. To better meet patient needs we have established a Pharmacist run cannabis consultation service (CCS). The rationale for the CCS, principles by which it operates, challenges and lessoned learned will be discussed.

Learning Objectives:

At the end of this presentation you will be able to discuss the:

  1. Canadian legislative framework governing cannabis use for medical purposes;
  2. components of the endocannabinoid system;
  3. evidence for the use of cannabis in oncology symptom management;
  4. cancer patient’s perspective on using cannabis for medical purposes; and
  5. role of pharmacists in managing cancer patients taking medical cannabis.
     
Concurrent session
New Treatments in Acute Lymphocytic Leukemia
Presenters
Marc Geirnaert
Photo of Marc Geirnaert
Photo of Marc Geirnaert
Marc Geirnaert
Director of Provincial Oncology Drug Program, Pharmacy, CancerCare Manitoba — Winnipeg, Manitoba
Marc Geirnaert
CancerCare Manitoba, Winnipeg, Manitoba

The presentation will provide a general overview of acute lymphocytic leukemia (ALL), treatment principles of ALL and provide an overview of the new therapies incorporated into practice over the last 2 years.

Learning Objectives:

  1. Understand treatment principles of ALL;
  2. Explain what is meant by the term “minimal residual disease”;
  3. Understand the use of blinatumomab and how to manage side effects;
  4. Understand the use of inotuzumab ozogamicin and how to manage side effects; and
  5. Review the role of CAR T-cell therapy in the treatment of ALL.
     
Satellite symposium
BD Canada - Ask Me Anything on Drug Waste Minimization Strategies with Dr. Alicia Wall
Presenters
Alicia Wall
Photo of Alicia Wall
Photo of Alicia Wall
Alicia Wall
BSc Pharm, Pharm D, MHA, CHE
Regional Director, Pharmacy Services, Pharmacy, Eastern Health — St. John's, Newfoundland and Labrador
Alicia Wall
Eastern Health, St. John's, Newfoundland and Labrador

The pervasive pandemic has challenged healthcare workers in more ways than one. From patient care, to supply continuity, drug shortages, as well as the incredible financial toll it has taken on Canadian hospitals. Join Dr. Alicia Wall in this timely discussion on drug waste minimization strategies, where she will discuss strategies employed at Eastern Health, such as beyond use date extension (i.e., drug vial optimization).

Sunday
June 6, 2021
All times indicated are Eastern Daylight Times (EDT).

Satellite symposium
Merck - The Pharmacist’s Role in Optimizing the Management of Patients on Immunotherapy: A Pre and Post Pandemic Perspective with Extended Interval Dosing
Presenters
Glenn Myers
Photo of Glenn Myers
Photo of Glenn Myers
Glenn Myers
BScPharm, ACPR, RPh
Clinical Pharmacist - Outpatient Medical Oncology, Pharmacy, Horizon Health Network — Moncton, New Brunswick
Glenn completed a BSc (Pharmacy) at Dalhousie University in 2011 and an Accredited Canadian Pharmacy Resident (ACPR) certificate at the Saint John Regional Hospital in 2011-12. He has been working in ambulatory medical oncology for 10 years and focuses his clinical interventions on the collaborative assessment and management of chemotherapy, oral anti-cancer and immune related adverse events. Glenn's research efforts focus on ambulatory practice based research and enjoys mentoring various levels of pharmacy learners.
Glenn Myers
Horizon Health Network, Moncton, New Brunswick

The COVID-19 pandemic has affected many aspects of oncology medical practice, including how clinics are managed. In some cases, new ways of scheduling treatments have emerged that have proven beneficial for patients and may endure post-pandemic. Join us at the CAPhO Virtual Conference 2021 for an interactive symposium guided by two experienced pharmacists who will review strategies as they relate to immunotherapy in the management of various cancers, and will illustrate with patient cases the application to current practice.

Poster Award Presentations
Break
Break amongst the Exhibits and Posters
Round table discussion
3. Working Toward NAPRA Hazardous Sterile Preparation Compliance: Implementing the Role of an IV Compounding Supervisor
Presenters
Colleen Thurber
Photo of Colleen Thurber
Photo of Colleen Thurber
Colleen Thurber
Senior Pharmacy Technician, Pharmacy, Saskatchewan Cancer Agency — Saskatoon, Saskatchewan
Colleen graduated with a Pharmacy Technician Certificate from SIAST in 1998 and started her career with the Royal University Hospital pharmacy department in Saskatoon, Saskatchewan the same year. She has worked as an oncology pharmacy technician at the Saskatoon Cancer Centre since 2004 and moved to a senior technician position in 2009. Colleen is also the Co-chairperson of the Occupational Health and Safety Committee at the Cancer Centre.
Colleen Thurber
Saskatchewan Cancer Agency, Saskatoon, Saskatchewan

The Model Standards for Pharmacy Compounding of Hazardous Sterile Preparations requires hospital pharmacies to implement an IV Compounding Supervisor, who is tasked with developing policies and procedures for training and assessing compounding personnel and overseeing the sterile compounding activities in the pharmacy. The Standards require the Supervisor be evaluated for knowledge and abilities by a third-party evaluator. We will discuss the challenges of achieving this while the world is dealing with COVID-19 restrictions, and steps technicians and pharmacists can take in the meantime. 

Round table discussion
2. A Pain in the L-asp; bridging treatment between Children and Adults with A.L.L.
Presenters
John Wiernikowski
John Wiernikowski
Clinical Pharmacist, Paediatric Haematology/Oncology, Paediatrics, McMaster Children's Hospital — Hamilton, Ontario
John Wiernikowski
McMaster Children's Hospital, Hamilton, Ontario

With discontinuation of native non-pegylated Asparaginase in Canada, PEG-asparaginase has become the defacto front line asparaginase product.  This discussion will focus on the importance of Asparaginase in the treatment of A.L.L.  and the challenges with delivering it (differing side effect/toxicity profiles, role of TDM) in these populations.

Round table discussion
1. Providing Oncology Services During the COVID-19 Pandemic: The New Normal
Presenters
Kimberly Kuik
Photo of Kimberly Kuik
Photo of Kimberly Kuik
Kimberly Kuik
BScPharm
Pharmacy Professional Practice Leader, Pharmacy, BC Cancer — Victoria, British Columbia
Kimberly Kuik
BC Cancer, Victoria, British Columbia

Opportunity to share innovative pharmacy practice implemented during the COVID-19 to support oncology patients.  Discuss the benefits, barriers and impact of changes utilized during this eventful time.

Round table discussion
6. From Opioid Mythbusting to Therapeutic Psychedelics: Palliative Oncology Hot Topics
Presenters
Chris Ralph
Photo of Chris Ralph
Photo of Chris Ralph
Chris Ralph
Clinical Pharmacist, Palliative Oncology, Complex Cancer Management Service, Tom Baker Cancer Centre — Calgary, Alberta

Chris Ralph is a clinical pharmacist with the Complex Cancer Management Service, an outpatient palliative oncology multidisciplinary team, at the Tom Baker Cancer Centre in Calgary. Chris has spoken at several regional, national, and international conferences over the years, and has co-authored a chapter in a palliative text published by Oxford University Press. Chris is a graduate of Memorial University of Newfoundland’s School of Pharmacy and a Fellow of CAPhO. Chris is especially curious about therapeutic use of psychedelics and medicinal cannabis, the placebo response, and nature as therapy. In his spare time, you’ll likely find Chris in the Rocky Mountains hiking, biking or skiing; playing guitar or his latest instrument – a Siberian hand-crafted handpan.
 

Chris Ralph
Tom Baker Cancer Centre, Calgary, Alberta

In this informal discussion we will explore palliative care clinical issues that face oncology pharmacists, with a focus on the outpatient setting, as well as looking at some of the hot topics in the realm of palliative care.

Round table discussion
5. Drug Access Navigation in Pandemic Times
Presenters
Kim O'Connor
Photo of Kim O'Connor
Photo of Kim O'Connor
Kim O'Connor
Drug Reimbursement Specialist (DAN) , Odette Cancer Centre Pharmacy, Sunnybrook Health Sciences Centre — Toronto, Ontario

Kim O’Connor, RPhT is a Drug Reimbursement Specialist (DAN) at the Sunnybrook Health Sciences Centre – Odette Cancer Centre Pharmacy. As a Registered Pharmacy Technician in Ontario, she has over 30 years of experience in the oncology setting that includes navigating drug access for patients, responsibly for compassionate and Special Access Program drugs, Oral Anti-Cancer Medication Team member, BPMH, and sterile product preparation. She is an ODANO member.

Kim obtained her Pharmacy Assistant Diploma from Algonquin College in Ottawa, Ontario in 1985 and her Certification and Registration with OCP from 2012-2015.

Kim O'Connor
Sunnybrook Health Sciences Centre, Toronto, Ontario

We are facing an increased challenge to connect with patients, Health Care Workers, Patient Support Programs, and government agencies during COVID-19 around drug access. We will discuss these challenges and offer shared experiences
on how we have worked to address them.
 

Round table discussion
4. Videos or Other Solutions to Enhance Patient Education
Presenters
Mova Leung
Mova Leung
Oncology Pharmacy Practitioner, Oncology, North York General Hospital — North York, Ontario
Mova Leung
North York General Hospital, North York, Ontario

Providing education materials in formats other than printed documentation can really help our diverse and aging patient population, whether it be for patient education, new staff orientation or other reasons.  Historically, considered costly and time consuming, creating videos are not as hard as they used to be! In this roundtable, we will some of the applications that are readily accessible so that you can create your own education or training video.  We'll discuss platforms that can support the dissemination of patient education material and share ideas and initiatives that are in development.

Networking Session
Plenary session
Opioid Risk Mitigation Strategies for Patients with Cancer: Putting Pharmacy in the Driver’s Seat
Presenters
Lauren Hutton
Dr. Jenny Lau
Photo of Lauren Hutton
Photo of Lauren Hutton
Lauren Hutton
Clinical Coordinator, Pharmacy, NSH — Halifax, Nova Scotia
Lauren Hutton
NSH, Halifax, Nova Scotia
Photo of Dr. Jenny Lau
Photo of Dr. Jenny Lau
Dr. Jenny Lau
Medical Director, Harold and Shirley Lederman Palliative Care Centre , Princess Margaret Cancer Center — Toronto, Ontario

Dr. Jenny Lau MD CCFP (PC) is the Medical Director of the Harold and Shirley Lederman Palliative Care Centre in Toronto, Canada’s Princess Margaret Cancer Center. She is a palliative care physician who trained in family medicine at the University of Ottawa and then completed her year of added competence in palliative care at the University of Alberta. Dr. Lau leads numerous local and national projects focused on promoting safer opioid use in the context of life-threatening illnesses. 

Dr. Jenny Lau
Princess Margaret Cancer Center, Toronto, Ontario

The conference theme of “Change, Challenge, Opportunity” is at the heart of this plenary session. In response to the increase in opioid-related deaths in Canada, national strategies and guidelines have been developed to help support both practitioners and patients in improving opioid use. Unfortunately, these strategies focus on opioid use for chronic non-cancer pain. During this session we will explore:

  • the impact of the opioid crisis on patients living with cancer related pain; 
  • some of the safety concerns around opioid use in patients with cancer;
  • how pharmacy’s unique position and high accessibility within the health care system amplifies its impact when implementing meaningful strategies to better support patients requiring opioids to manage cancer related pain; and
  • the current and future direction of research in Canada on this topic and how you can engage with initiatives and practices to best support your patients living with cancer related pain.

We hope you leave this session feeling informed and empowered to collaborate with both your patients and inter-professional health care teams to ensure patients with cancer are receiving the most effective pain control strategies and are supported and educated regarding using these therapies safely. 

Learning Objectives:

  1. Describe the current opioid crisis in Canada;
  2. Explain the role of opioids in management of cancer-related pain;
  3. Develop a monitoring plan (safety and efficacy) for a patient receiving opioids for cancer-related pain;
  4. Incorporate the World Health Organization guidelines into your pharmaceutical care process for patients receiving opioids for cancer related pain; and
  5. Summarize pharmacy-sensitive practices that you can implement/champion in your practice setting or institution.
Satellite symposium
Apobiologix - 2021 HOPE Award Presentations and NEW Educational Initiatives
Presenters
Lauren (Flay) Charbonneau
Scott Edwards
Dr. Nirmesh Shah
Photo of Lauren (Flay) Charbonneau
Photo of Lauren (Flay) Charbonneau
Lauren (Flay) Charbonneau
Manager, Pharmacy, Pharmacy, Sunnybrook Health Sciences Centre — Toronto, Ontario
Pharmacy manager at Odette Cancer Centre at Sunnybrook Health Sciences Centre in Toronto, ON. Long time CAPhO and organizing committee member. Oncology pharmacy education is so important to what we do every day.
Lauren (Flay) Charbonneau
Sunnybrook Health Sciences Centre, Toronto, Ontario
Photo of Scott Edwards
Photo of Scott Edwards
Scott Edwards
Clinical Pharmacy Specialist, Pharmacy, Eastern Health — st john's, Newfoundland and Labrador
Scott Edwards
Eastern Health, st john's, Newfoundland and Labrador
Dr. Nirmesh Shah
Dr. Nirmesh Shah

This important symposium will feature the first ever HOPE (Honouring Oncology Pharmacy Excellence) award recipients (to be announced), who will showcase their award-winning submissions.
 
You will also learn about a new educational initiative called ABC – Addressing the Basics in Cancer, to be launched later this fall.
 
The speakers will include Flay Charbonneau from Ontario, who will introduce the HOPE Awards, Scott Edwards, from Newfoundland, who will present the ABC program, and Dr. Nirmesh Shah from Apobiologix, who will provide an overview of the APP.